From: Impact of vitamin D level in diabetic people with peripheral neuropathy
Item | Group A (n = 20) | Group B (n = 20) | Group C (n = 20) | Control group (n = 20) | χ2/KWT | p-value | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |||||||
Duration of DM (years) | ||||||||||||||
Mean ± SD | 8.95 ± 3.42 | 8.7 ± 3.63 | 7.6 ± 2.94 | 3.6 ± 1.2 | 14.86 | 0.001* (HS) | ||||||||
Median (range) | 9 (4–15) | 8 (3–17) | 7 (3–14) | 3 (1–6) | ||||||||||
The current hypoglycemic drug | ||||||||||||||
Insulin | 10 | 50% | 8 | 40% | 8 | 40% | 9 | 45% | 4.81 | 0.850 (NS) | ||||
Glimepiride | 3 | 15% | 5 | 25% | 6 | 30% | 5 | 25% | ||||||
Gliclazide | 6 | 30% | 3 | 15% | 4 | 20% | 3 | 15% | ||||||
Combined preparation | 1 | 5% | 4 | 20% | 2 | 10% | 3 | 15% | ||||||
Score of neuropathy (TCSS) | ||||||||||||||
Mean ± SD | 12.25 ± 2.14 | 7.6 ± 1.09 | 9.70 ± 2.02 | 0.95 ± 1.19 | 63.39 | 0.000* (HS) | ||||||||
Median (range) | 12.5 (9–15) | 8(6–9) | 9 (7–14) | 0.5 (0–4) | ||||||||||
Stage of diabetic foot | ||||||||||||||
Normal foot | 12 | 60% | 20 | 100% | 0 | 0% | 20 | 10 | 65.11 | 0.001* (HS) | ||||
Ulcerated | 4 | 20% | 0 | 0% | 17 | 85% | 0 | 0 | ||||||
Infected | 3 | 15% | 0 | 0% | 2 | 10% | 0 | 0 | ||||||
Necrotic | 1 | 5% | 0 | 0% | 1 | 5% | 0 | 0 |